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Abstract Expressed sequence tag (EST) databases represent a
large volume of information on expressed genes including tissue
type, expression profile and exon structure. In this study we
create an extensive data set of human alternative splicing. We
report the analysis of 7867 non-redundant mRNAs, 3011 of
which contained alternative splice forms (38% of all mRNAs
analysed). From a total of 12 572 ESTs 4560 different possible
alternative splice forms were detected. Interestingly, 70% of the
alternative splice forms correspond to exon deletion events with
only 30% exonic insertions. We experimentally verified 19
different splice forms from 16 genes in a total subset of 20
studied; all of the respective genes are of medical relevance.
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1. Introduction
There are over 1.5 million human expressed sequence tags
(ESTs) in the public databases representing a wide variety of
di¡erent tissue types, including diseased, normal and immor-
talised cell lines. In addition many di¡erent time points in
human development are covered (from embryos to late adult-
hood). This variety of ESTs provides an ideal resource to
examine a number of biological questions concerning gene
expression and structure. One such question is that of alter-
native splicing (AS). AS is an important mechanism allowing
tissue-speci¢c or temporal expression of a novel gene form.
AS allows one pre-mRNA to be processed into many di¡erent
mature forms within a cell, each of which can have distinct
functions. AS allows tissues to express a single splice variant
or a ratio of several forms. Estimates of AS range from 5 to
30% for speci¢c tissue types [1,2]. AS has also been shown to
be speci¢cally associated with disease phenotypes [3,4]. The
purpose of this study was threefold. Firstly, to develop a
computational method by which large numbers of human
AS forms could be detected by comparison with ESTs. Sec-
ondly, to create a database of novel candidate AS forms. This
could act as a primary resource to examine the alternative
splicing of speci¢c genes of interest or as diagnostic markers
of disease tissue. Finally, to experimentally validate the pre-
dictions on a subset of medically relevant genes. This not only
enhances experimental identi¢cation of splice sites but also
hints at the accuracy of the method.
2. Materials and methods
2.1. Computational approach
Twelve thousand and thirty-three radiation hybrid mapped mRNA
sequences were downloaded from the current release (20.1.2000) of
the NCBI Genemap (ftp://ncbi.nlm.nih.gov/repository/genemap/
Mar1999/) (see Fig. 1). To remove redundant sequences with identical
sequences but di¡erent annotation, the script ‘nrdb’ was used from the
same NCBI site. This reduced the total to 10 226. To remove partial
sequences and published truncated forms, each sequence was matched
against the EST database with BLASTN [5]. If an EST matched two
or more sequences with an expect value greater than 1e330, only the
best scoring sequence was retained in the data set; this reduced the
total to 7867 mRNAs. To extract candidate alternative splice forms,
in-house written software compared end positions of ESTs with those
of the remaining genes from GenBank. The BLASTN program was
used with an Expect value 1e330 without gaps. To prevent frame-
shifts in the ESTs from producing false alignments BLASTN param-
eter X = 1 was used. To reduce the risk of contamination of our set
with pseudogenes or paralogous sequences, stringent parameters were
used. For a possible AS form to be considered the combined align-
ment of each piece had to have an identity of over 97%. Filter pro-
grams to extract possible AS forms and remove false ones were writ-
ten in Perl and C. The default BLASTN ¢lter DUST was used to
exclude simple repeats present in the mRNAs. Further ¢ltering was
applied to remove matches representing internally repeated domains
within mRNAs. Such situations caused many false positives and in-
deed, this ¢lter removed 376 candidates.
2.2. Experimental approach
For each of the candidates tested, primers were designed from each
end of a candidate EST to allow ampli¢cation of possible PCR prod-
ucts from a cDNA multiple tissue panel (MTC) panel 1 (Clontech). In
certain cases primers were designed to exons either side of a candidate
splice form. For details of PCR conditions see legend to Fig. 2. Com-
plete experimental results including gel pictures and sequences are to
be found at the following site: ftp://ftp.bioinf.mdc-berlin.de/pub/data-
base/SPLICE_SITE/method.html.
3. Results
After employing the ¢lters, methods and stringent parame-
ters described in Section 2, we generated 4600 possible candi-
dates. In addition to the expected insertions and deletions of
sequence regions, 40 possible rearrangements were detected.
However, on closer examination, the majority of these were
arti¢cial and were in fact the result of internally repeated
domains within the mRNA sequence. For only ¢ve possible
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rearrangements, no obvious explanation was found. As none
of these could be experimentally veri¢ed, we treated possible
rearrangements as false positives. After errors and possible
rearrangements were removed this left 4560 candidate splice
forms from 3011 human mRNAs. Within this list we identi-
¢ed 1368 inserts and 3192 exon deletions.
The resulting database of AS forms (ftp://ftp.bioinf.
mdc-berlin.de/pub/database/SPLICE_SITE/MRNA/humrna.
html) contains all candidates ESTs identi¢ed and the respec-
tive genes. SwissProt disease-associated proteins with their
corresponding EST candidate AS forms are labelled in
their own table (ftp://ftp.bioinf.mdc-berlin.de/pub/database/
SPLICE_SITE/disease475.html).
To get some information on the accuracy of the method,
experimental veri¢cation was attempted on 20 candidate
genes. Approximately half of these genes were chosen from
the list in collaboration with a number of di¡erent clinical
research groups as possible diagnostic markers of disease.
The others were chosen as genes of special interest to a par-
ticular research group. Despite this directed selection, the
20 genes show no particular bias towards length, chromoso-
Fig. 1. A £ow diagram of the bioinformatic method used to extract alternative splice forms found within ESTs from a collection of 12 033
mRNA radiation hybrid mapped sequences.
Fig. 2. Human muscle phosphoglycerate mutase de¢ciency is associ-
ated with exercise intolerance, muscle cramps, chronic serum crea-
tine kinase elevation, and recurrent episodes of myoglobinuria. A:
The patterned boxes show the normal order of the three exons. The
lower of the two graphics shows a complete deletion of exon 2
(178 bp) found within EST AI305267. The numbers are derived
from GenBank entry J05073. B: Primers designed to either side of
exon 2 produced two bands, a larger approximately 500 bp band
plus a lower approximately 320 bp band (lanes 1). The PCR prod-
uct was concentrated and the bands cut from the gel and run in
lane 2 (lower band) and lane 4 (upper band) as a comparison. Lane
6 is the marker lane; the more prominent marker band is approxi-
mately 500 bp. Conditions: A 30 cycle PCR was performed at 92‡C
for 1 min, 58‡C for 1 min, 72‡C for 1 min with a 72‡C extension
for 10 min on the last cycle. If these standard conditions failed to
give a clear result the 58‡C step was varied in a range from 55 to
65‡C. Eight di¡erent tissues are represented on the panel: from 1 to
8 brain, heart, kidney, liver, lung, pancreas, placenta, skeletal
muscle. Products were run out on a 1% agarose gel, excised, cleaned
and direct sequencing was attempted.
Fig. 3. BIGH3 is a surface recognition protein, inducible by trans-
forming growth factor L [14]. Mutations of the protein have been
shown to cause lattice corneal dystrophy [15]. A: In EST AA037281
we identi¢ed a novel transcript. After designing primers from exon
10 and 11 the PCR sequence included an extension of the 5P end of
exon 11 by 411 bp. Numbers are derived from genomic sequence (gi
2996635) comparison. B: Both the novel extended sequence (larger
band 1064 bp) and the sequence matching the published mRNA
(lower band of 653 bp) are seen in seven of eight tissues examined
(lanes 3^9). As in Fig. 2B the outer lanes are lambda markers and
lane 10 is a 1 kb ladder. Both published sequence (lower band of
653 bp) and extended exon 11 (higher band of 1064 bp) are absent
from lane 2 representing brain. Lane 9 representing skeletal muscle
produced both bands (very faint).
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mal localisation, function, type, etc., although every candidate
has some either direct or indirect in£uence on a disease phe-
notype. From the 20 candidate alternatively spliced genes,
four produced only the published mRNA sequence (alterna-
tive EST sequence not con¢rmed). From the other 16, we were
able to verify 19 splice forms which were alternatives to the
published mRNA sequence (see Table 1). All candidate AS
forms were present in at least two di¡erent tissue types. For
an example of experimental veri¢cation of deletion or inser-
tion of a sequence within a published exon, see Figs. 2 and 3.
4. Discussion
In our ¢nal test set of 7867 mRNAs (Fig. 1), we could
extract 4560 candidate AS forms in 3011 human mRNAs.
Approximately 38% of the proteins tested seem to be alter-
natively spliced and on average, 2.75 splice forms exist per
spliced gene. In a recent smaller study of 475 proteins, we
detected 34% alternative splicing using the same BLAST pa-
rameters [6]. Both studies produced a similar ratio of genes
exhibiting alternative splicing. However, in the new study the
ratio of di¡erent ESTs covering a single candidate AS site
doubled from on average two per site to four. One possible
reason for this is the inclusion of untranslated regions (UTRs)
in the new study. The generally increased prevalence of ESTs
matching the 3P UTR of an RNA may give rise to this in-
crease in ratio. It is interesting to note that the inclusion of
UTR sequences had little e¡ect on the level of alternative
splicing. This is in contrast to single nucleotide polymorphism
(SNP) in which selection seems stronger in the coding regions
[7]. The rate of AS in exons encoded by UTRs did not sig-
ni¢cantly di¡er from coding exons in our study.
The estimate of AS in human mRNAs based on this study
is still likely to be an underestimate as published mRNAs
evidently exclude intronic information. Novel splice variants
could occur in published introns not detectable by this study.
In addition the ESTs used as primary source represent on
average only four di¡erent ESTs per RNA query. Although
this is an increase on the previous study, this sampling ratio
represents only a small number of the possible tissue types or
time points present in vivo. From an SNP study carried out
on a similar large number of human mRNAs, we calculated
an approximate coverage of 30% of exons within our study set
[7]. 30% of the possible splice forms found with ESTs arose
through insertion of a sequence. Within this group we esti-
mate 8% of inserts will be false positives (2.4% of all 4560
candidates) due to pre-mRNA or genomic DNA contamina-
tion of the EST database. This estimate was derived from an
analysis of 137 proteins with their corresponding genomic
sequences from the smaller pilot study [6].
The experimental validation of AS in 16 out of 20 genes
was performed as a proof of principle of the extraction meth-
od (see Table 1). Although this number is too small to make a
statistical calculation for the whole set, 80% of predicted
splice forms con¢rm a signi¢cant success rate. The remaining
20% (four cases) cannot be taken as a direct re£ection of a
false positive rate. The failure of the experimental technique
to ¢nd four of the possible candidates may be a simple func-
tion of low abundance of that particular form or its existence
in a rare tissue type. In two of the four cases where no alter-
native splice form was identi¢ed (only published mRNA se-
quence found), the genomic information indicated no contam-
ination with pre-mRNAs or DNA. In the other two cases, no
genomic sequence was available. However, it is interesting to
note that in all four cases inserts to exons were predicted. In
another 10 cases where genomic sequences were available, but
no experiment was performed, the candidates were also man-
ually examined for possible pre-mRNA or DNA contamina-
tion of the EST sequence. No indication of any of these events
was found.
From the 16 candidate genes experimentally veri¢ed, 13
have been shown in the literature to have a direct e¡ect in
the development of disease phenotypes. In four cases splice
forms of the gene are associated with disease. Speci¢c splice
Table 1
Listed are 16 genes (mRNA or protein entries) with 19 alternative splice forms that di¡er from the published mRNA sequence
mRNA or protein Swiss-Prot No. or gi No. EST Number of tissues expressed in Splice form Positiona
PMGM 189867 AI305267 8 178 bp deletion Exon 2
PYR5 J03626 AA331635 7 153 bp deletion CDS
HLA class I X13111 AA838034 8 32 bp insert Exon 5
HPS U79136 AA700609 8 521 bp deletion 3P UTR
TM4SF 3152700 AA133048 6 76 bp insert 3P UTR
Leucophysin 425353 AA005421 8 103 bp insert 5P UTR
SYK kinase 4507328 AA009756* 6 69 bp insert CDS
CDC16 603230 AA010055 8 79 bp insert 3P UTR
GRB7 601890 AA010229 8 219bp insert Exon 9
Sialyltransferase 3169563 AA015645 8 201 bp insert 5P UTR
GNB3 M31328 W27169 3 144 bp insert Exon 10
AA767991* 3 123 bp deletion Exon 9
PPAR-Q P37231 AA053612 5 184 bp deletion 5P UTR
AA298089 2 144 bp deletion 5P UTR
BIGH3 3282161 AA037281 7 411 bp insert Exon 11
NOS3 266648 AA994247 2 31 bp insert Exon 23
CROC4 5453625 AA013012 2 96 bp deletion 5P UTR
2 252 bp deletion CDS
SDR-1 homolog AF035287 AA130752 4 54 bp insert CDS
Each alternative splice form was experimentally veri¢ed in at least two di¡erent tissues. A search of the literature for each gene showed that of
the 19 splice forms only two were published (EST marked with an *). One of these alternative splice forms detected within the GNB3 protein
had previously been studied in connection with hypertension [9]. CDC16 splice form was noted in a direct submission GenBank entry
(AF164598) of that gene. For details of particular tissue types, gel pictures and sequence information see WWW page listed in Section 2.
aWhere CDS is reported as position, no genomic information was available.
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forms of peroxisome proliferator-activated receptor Q (PPAR-
Q) have been linked to the development of obesity [8]. GNB3
alternative splicing is associated with a hypertensive pheno-
type [9]. A novel splice variant of Grb7 is associated with
invasive carcinoma [10]. Selective loss of speci¢c HLA splice
variants is associated with melanoma progression [11]. In all
four of these cases we have found additional novel splice
forms. In the other cases (HPS and SYK genes) alternative
splicing is known to occur with as yet no direct disease asso-
ciation [12,13]. All these examples show the important role
that alternative splicing plays in human disease. In the near
future we expect both the number of human mRNAs and
ESTs deposited in public access databases to grow consider-
ably. Regular updating of our data set should provide a very
useful resource for clinical investigators. Our database di¡ers
from a published database of alternative splice forms ASDB
(http://cbcg.nersc.gov/asdb) as we used ESTs to ¢nd novel
human AS forms. ASDB at present uses only key words to
extract AS forms that are already published in GenBank or
SwissProt. As this article was in preparation a smaller-scale
study of alternative splice forms found in ESTs was published.
This mirrors our pilot study in that the authors used 392
genes, it also con¢rms a similar rate of alternative splicing,
38% of genes in this case [16].
In conclusion, this study provides a vast number of human
candidate AS forms with a high con¢dence level. The results
are accessible in a database that currently contains 4560 can-
didate AS forms from 3011 human mRNAs, many of which
have a direct role in disease progression.
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